Modality
Peptide
MOA
GLP-1/GIP
Target
TIM-3
Pathway
Ferroptosis
Huntington'sPNHAtopic Derm
Development Pipeline
Preclinical
~May 2022
→ ~Aug 2023
Phase 1
~Nov 2023
→ ~Feb 2025
Phase 2
May 2025
→ Aug 2031
Phase 2Current
NCT04991758
237 pts·Huntington's
2025-12→2031-08·Not yet recruiting
NCT04783581
825 pts·Huntington's
2025-05→2025-12·Active
1,062 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-094mo agoPh3 Readout· Huntington's
2031-08-195.4y awayPh3 Readout· Huntington's
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Active
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-12-09 · 4mo ago
Huntington's
Ph3 Readout
2031-08-19 · 5.4y away
Huntington's
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04991758 | Phase 2/3 | Huntington's | Not yet recr... | 237 | DOR |
| NCT04783581 | Phase 2/3 | Huntington's | Active | 825 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 | |
| Rimanesiran | Merus | Phase 1 | TIM-3 | |
| BEA-4274 | Beam | Phase 1/2 | ALK |